Table 1.
Clinicopathologic findings in the TAC and SRL groups.
| Variable | Categorical Value | TAC (n = 22) | SRL (n = 20) | p Value |
|---|---|---|---|---|
| Preoperative factors | ||||
| Recipient Sex | Male | 21 (95%) | 19 (95%) | 1.00 |
| Age (Years) | Mean ± SD | 56.86 ± 6.40 | 51.95 ± 7.63 | 0.03 |
| Hypertension | n (%) | 5 (22.7) | 4 (20.0) | 1.00 |
| DM | n (%) | 6 (27.3) | 8 (40.0) | 0.52 |
| BMI (kg/m2) | Mean ± SD | 24.23 ± 3.05 | 25.04 ± 3.79 | 0.45 |
| MELD Score | Mean ± SD | 11.18 ± 9.10 | 8.95 ± 5.35 | 0.35 |
| CPT Score, n (%) | n (%) | 0.01 | ||
| A | 13 (59.1) | 10 (50.0) | ||
| B | 3 (13.6) | 10 (50.0) | ||
| C | 6 (27.3) | 0 (0) | ||
| Serum Creatinine (mg/dL) | Median | 0.93 (0.58–1.8) | 0.86 (0.57–1.3) | 0.27 |
| Donor Sex | Male | 13 (59.1%) | 14 (70%) | 0.53 |
| Donor Age | Median | 32 (18–53) | 25.5 (17–53) | 0.36 |
| Primary Liver Disease | n (%) | 0.40 | ||
| HBV | 17 (77.3) | 18 (90.0) | ||
| HCV | 1 (4.5) | 1 (4.2) | ||
| Alcoholism | 3 (13.6) | 0 (0) | ||
| Others | 1 (13.6) | 1 (4.2%) | ||
| Pre-LT Treatment | n (%) | |||
| TACE | 16 (72.7) | 15 (62.5) | 0.46 | |
| RFA | 2 (9.1) | 3 (15.0) | 0.66 | |
| PEIT | 2 (9.1) | 1 (8.3) | 1.00 | |
| Surgery | 3 (13.6) | 3 (12.5) | 1.00 | |
| AFP (ng/mL) | Mean ± SD | 317.93 ± 1274.23 | 706 ± 2916.97 | 0.57 |
| Median | 18.55 (2.7–6010) | 15.3 (2.4–14,070) | 0.49 | |
| ≤150 | n (%) | 19 (86.4) | 16 (80.0) | 0.69 |
| >150 | n (%) | 3 (13.6) | 4 (20.0) | |
| ≤400 | n (%) | 21 (95.5) | 17 (85%) | 0.27 |
| >400 | n (%) | 1 (4.5) | 3(15%) | |
| PET SUV ratio | Median | 1.02 (0.91–1.68) | 1.17 (0.82–3.39) | 0.35 |
| ≤1.15 | 13 (76.5) | 8 (50) | 0.16 | |
| >1.15 | 4 (23.5) | 8 (50) | ||
| Intraoperative factors | ||||
| GRWR | Mean ± SD | 1.18 ± 0.31 | 1.14 ± 0.28 | 0.69 |
| Cold Ischemia Time (min) | Mean ± SD | 63.3 ± 26.72 | 78.98 ± 21.29 | 0.05 |
| Warm Ischemia Time (min) | Mean ± SD | 33.33 ± 9.71 | 29.99 ± 8.02 | 0.23 |
| EBL (Ml) | Median | 1475 (400–23,000) | 1625 (500–12,000) | 0.68 |
| RBC Transfusion (Units) | Median | 0.5 (0–36) | 2 (0–24) | 0.61 |
| Pathologic Factors | ||||
| Tumour Number | Median | 3.5 (1–8) | 4.5 (1–11) | 0.33 |
| Tumour Maximum Size (cm) | Median | 3.8 (0.9–8) | 3.65 (2–10) | 0.55 |
| Tumour Sum Size (cm) | Mean ± SD | 7.59 ± 4.68 | 9.01 ± 3.44 | 0.25 |
| Microvascular Invasion | n (%) | 5 (22.7) | 5 (25.0) | 1.00 |
| Portal Vein Invasion | n (%) | 0 (0) | 0 (0) | NA |
| Bile Duct Involvement | n (%) | 1 (4.5) | 0 (0) | 1.00 |
| Mean tumour necrosis after TACE | Median | 61.6 (0–100) | 31 (0–99) | 0.26 |
| ES grade, n (%) | 0.13 | |||
| 1 | 1 (4.5) | 0 (0) | ||
| 2 | 4 (19.2) | 9 (45.0) | ||
| 3 | 12 (54.5) | 10 (50.0) | ||
| 4 | 5 (22.7) | 1 (5.0) | ||
|
Immunosuppression Trough Level of TAC or SRL |
Median | |||
| 3 Months | 5.1 (0.6–12.6) | 4.5 (1.6–15.1) | ||
| 6 Months | 8.5 (4.9–15.2) | 6.8 (2–30) | ||
| MMF dosage at 3 months | n (%) | |||
| ~500 mg/day | 0 | 1 (5.0) | ||
| 1000 mg/day | 17 (77.3) | 15 (75.0) | ||
| 1500 mg/day | 5 (22.7) | 4 (20.0) | ||
| HCC related outcome | ||||
| Time to LT | Median | 17 (0–107) | 2 (0–108) | 0.08 |
| Event of Recurrence | n (%) | 8 (36.4) | 5 (25) | 0.43 |
| Time to Recurrence | Median | 7 (5–31) | 15 (6–45) | 0.46 |
| Event of Death | n (%) | 7 (31.8) | 2 (10) | 0.14 |
TAC, tacrolimus; SD, standard deviation; SRL, sirolimus; DM, diabetes mellitus; BMI, body mass index; MELD, model for end-stage liver disease; CPT, Child-Pugh-Turcotte; HBV, hepatitis B; HCV, hepatitis C; LT, liver transplantation; TACE, transarterial chemoembolisation; RFA, radiofrequency ablation; PEIT, percutaneous ethanol injection therapy; AFP, alpha-fetoprotein; PET, positron emission tomography; SUV, standardised uptake value; GRWR, graft-to-recipient weight ratio; EBL, estimated blood loss; RBC, red blood cell; ES, Edmondson and Steiner; NA, not available.